Patient Education Guide
Wegovy Pill vs Mounjaro: Which Weight Loss Treatment Is Better?
The Direct Answer: Neither the Wegovy Pill nor Mounjaro is universally 'better' — they serve different patients with different priorities. Mounjaro (tirzepatide) produces greater average weight loss (~22.5% over 72 weeks) and works via a dual GLP-1 and GIP mechanism. The Wegovy Pill (oral semaglutide) is needle-free, taken daily as a tablet, and produces around 14–17% weight loss. The right choice depends on your BMI, health history, tolerance for injections, daily routine, and budget. This guide compares all three options — the Wegovy Pill, the Wegovy injection, and Mounjaro — across every dimension that matters.~14–17%Wegovy Pill
OASIS-4 / OASIS 1 (68 wks)
OASIS-4 / OASIS 1 (68 wks)
~20.7%Wegovy Injection 7.2mg
STEP UP (72 wks)
STEP UP (72 wks)
~22.5%Mounjaro 15mg
SURMOUNT-1 (72 wks)
SURMOUNT-1 (72 wks)
How They Work
1. How Each Treatment Works: The Mechanism Difference
All three treatments work by activating hormonal receptors in the brain and body that regulate appetite, satiety, and blood sugar — but they do so through different pathways, and this difference matters clinically.
GLP-1: The Shared Pathway
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals fullness to the brain, slows stomach emptying, and stimulates insulin release in response to food. Both the Wegovy Pill and the Wegovy injection activate GLP-1 receptors — as does Mounjaro, but in combination with a second pathway.
GIP: Mounjaro's Additional Mechanism
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works alongside GLP-1 to regulate appetite, fat storage, and metabolism. Mounjaro (tirzepatide) is the first medicine to activate both GLP-1 and GIP receptors simultaneously — a dual agonist mechanism that is believed to explain its superior average weight loss compared to GLP-1 monotherapy alone.
In practical terms, the GIP pathway in Mounjaro appears to amplify the appetite-suppressing and metabolic effects of GLP-1 stimulation, leading to more consistent and greater weight loss across the patient population. This is not a minor incremental difference — the gap between Mounjaro 15mg (~22.5%) and semaglutide 2.4mg (~15%) in clinical trials is roughly seven percentage points, which can represent several kilograms of additional weight loss over the treatment period.
The Wegovy Pill: Same Molecule, Different Delivery
The Wegovy Pill contains exactly the same active ingredient as the Wegovy injection — semaglutide — and activates the same GLP-1 receptors. The only difference is delivery method: the pill uses the SNAC oral absorption system to carry semaglutide through the stomach wall, while the injection delivers it subcutaneously. This means the pill and the injection are broadly equivalent in mechanism and results at their standard doses, despite the very different routes of administration.
| Wegovy Pill | Wegovy Injection | Mounjaro |
|---|---|---|
| Oral semaglutide 25mg daily | Semaglutide 2.4mg or 7.2mg weekly | Tirzepatide 5mg–15mg weekly |
| Mechanism: GLP-1 receptor agonist | Mechanism: GLP-1 receptor agonist | Mechanism: Dual GLP-1 + GIP receptor agonist |
| Delivery: Tablet taken daily via SNAC absorption system | Delivery: Self-injected subcutaneously once a week | Delivery: Self-injected subcutaneously once a week |
| Targets: GLP-1 receptors only | Targets: GLP-1 receptors only | Targets: GLP-1 AND GIP receptors |
ℹ️ What the Mechanism Difference Means for You
If your priority is maximum weight loss and you are comfortable with injections, Mounjaro's dual mechanism offers a meaningful clinical advantage. If you want to avoid injections entirely, the Wegovy Pill delivers GLP-1 monotherapy results — comparable to the standard 2.4mg injection — without a single needle. The Wegovy 7.2mg injection sits in between, offering greater weight loss than the pill while remaining a GLP-1 monotherapy.
Head-to-Head Data
2. Efficacy: Head-to-Head Clinical Trial Data
Clinical trial results are the most objective basis for comparing weight loss treatments. The following data is drawn from each medicine's key Phase 3 registration trials — the gold standard of clinical evidence.
The data tells a clear story at the extremes: Mounjaro 15mg and the Wegovy 7.2mg injection lead on average outcomes, while the Wegovy Pill and the 2.4mg injection are closely matched with each other. The Wegovy Pill is not inferior to the standard injection — it simply cannot yet match the results achievable with higher-dose injectables or Mounjaro's dual mechanism.
One important caveat: clinical trial populations are carefully selected and follow strict protocols. Real-world results vary more widely than trial averages suggest, and individual response to any of these medicines can differ significantly. A patient who responds exceptionally well to semaglutide may achieve results that exceed the Mounjaro average — and vice versa.
| Wegovy Pill (25mg) | Wegovy Inj. 2.4mg | Wegovy Inj. 7.2mg | Mounjaro (15mg) | |
|---|---|---|---|---|
| Key trial | OASIS-4 | STEP 1 | STEP UP | SURMOUNT-1 |
| Trial duration | 68 weeks | 68 weeks | 72 weeks | 72 weeks |
| Average weight loss | 14–17% | ~15% | ~20.7% | ~22.5% |
| Lost ≥5% body weight | 78–85% | 86% | ~90% | 91% |
| Lost ≥10% body weight | ~69% | 69% | ~80% | 79% |
| Lost ≥15% body weight | ~52% | 50% | ~66% | 66% |
| Lost ≥20% body weight | ~34% | 32% | ~33% | 48% |
| Lost ≥25% body weight | Not reported | ~10% | ~33% | 31% |
| Waist reduction (avg) | −13.4 cm | ~−13.5 cm | ~−18 cm | ~−20 cm |
| BP improvement | Yes | Yes | Yes | Yes |
| HbA1c improvement | Yes | Yes | Yes | Significant — approved for T2D |
💡 The Individual Response Factor
Average trial results are exactly that — averages. Some patients lose significantly more than the trial mean on all three treatments; others lose less. A clinical trial result is a starting point for expectations, not a guarantee. Your prescriber can help you interpret what the evidence means for your specific situation.
Daily Life
3. Convenience and Daily Life
For many patients, the practical realities of treatment — how it fits into daily life — are just as important as clinical efficacy. The three treatments differ significantly in how they are taken and what they ask of the patient day to day.
The Wegovy Pill's daily dosing and morning routine requirement is its most significant practical trade-off. Weekly treatments — whether Wegovy injection or Mounjaro — offer substantially more flexibility, with no restrictions on when or what you eat. For patients with demanding or unpredictable daily schedules, this difference in convenience is clinically relevant, because a treatment that fits your life is a treatment you will actually take consistently.
| Wegovy Pill | Wegovy Injection (any dose) | Mounjaro | |
|---|---|---|---|
| Frequency | Once daily | Once weekly | Once weekly |
| Method | Tablet — no needle | Self-injection (pen) | Self-injection (pen) |
| Timing restrictions | Morning only, fasted, 30-min wait | Any time of day, with or without food | Any time of day, with or without food |
| Needle-free | Yes | No | No |
| Travel considerations | Tablets in hand luggage; measure 120ml water | Pens in hand luggage; no refrigeration in transit needed | Pens in hand luggage; no refrigeration in transit needed |
| Shift work suitability | Manageable — anchor to waking time | Excellent — full flexibility | Excellent — full flexibility |
| Forgotten dose impact | Skip and resume next morning | Take up to 5 days late, then continue | Take up to 4 days late, then continue |
| Disposal | Tablet packaging recycled normally | Sharps bin required | Sharps bin required |
Dose Escalation
4. Dosing: How Each Treatment Is Escalated
All three treatments use a gradual dose escalation schedule, starting at a low introductory dose and building to the maintenance dose over several months. This approach minimises gastrointestinal side effects and allows the body to adjust to the medicine.
Mounjaro takes the longest to reach its full maintenance dose — approximately six months — meaning the strongest results are seen later in treatment. The Wegovy Pill reaches its maintenance dose fastest at around four months, though the early doses (1.5mg to 9mg) contribute meaningfully to appetite reduction and early weight loss before the full 25mg dose is reached.
| Month | Wegovy Pill | Wegovy Injection | Mounjaro |
|---|---|---|---|
| Month 1 | 1.5 mg daily | 0.25 mg weekly | 2.5 mg weekly |
| Month 2 | 4 mg daily | 0.5 mg weekly | 5 mg weekly |
| Month 3 | 9 mg daily | 1 mg weekly | 7.5 mg weekly |
| Month 4 | 25 mg daily | 1.7 mg weekly | 10 mg weekly |
| Month 5+ | 25 mg daily (maintenance) | 2.4 mg weekly (maintenance) | 12.5 mg weekly |
| Month 6+ | 25 mg daily (maintenance) | 2.4 mg or 7.2 mg weekly | 15 mg weekly (maintenance) |
| Time to maintenance | ~4 months | ~5 months | ~6 months |
Tolerability
5. Side Effects: What to Expect on Each Treatment
All three treatments share a broadly similar side effect profile driven by their GLP-1 mechanism — primarily gastrointestinal effects during dose escalation. The key differences lie in frequency, severity, and a small number of treatment-specific effects.
A meaningful practical distinction: the Wegovy Pill carries no risk of injection site reactions — redness, bruising, or localised discomfort at the injection site that some patients find troublesome with both Wegovy injection and Mounjaro. This is a genuine, if minor, tolerability advantage for needle-averse patients or those with sensitive skin.
Mounjaro and the higher-dose Wegovy 7.2mg injection tend to produce somewhat more gastrointestinal side effects than the standard 2.4mg injection or the pill, particularly in the early months. However, discontinuation rates across all four treatments are low, and most patients find side effects improve substantially once the maintenance dose is established.
| Side effect | Wegovy Pill | Wegovy Inj. 2.4mg | Wegovy Inj. 7.2mg | Mounjaro 15mg |
|---|---|---|---|---|
| Nausea | Very common | Very common | Common — more frequent | Very common |
| Vomiting | Very common | Very common | More frequent | Common |
| Diarrhoea | Very common | Very common | More frequent | Common |
| Constipation | Very common | Very common | Similar | Very common |
| Headache | Very common | Common | Similar | Common |
| Injection site reactions | None — no injection | Common | Common | Common |
| Skin sensations (dysaesthesia) | Not reported | Rare | ~23% at 7.2mg | Not commonly reported |
| Hair thinning | Uncommon | Uncommon | Uncommon | Uncommon |
| Side effects improve over time | Yes | Yes | Yes | Yes |
| Discontinuation due to side effects (trial) | ~5% | ~5% | ~5.4% | ~5–7% |
✅ Managing Side Effects Across All Three Treatments
- Follow the dose escalation schedule — never rush to the next dose
- Eat smaller, more frequent meals, particularly in the first two months
- Avoid rich, fatty, or strongly spiced foods during the escalation phase
- Stay well hydrated — sip cold water regularly throughout the day
- Contact your prescriber if side effects are severe or persist beyond 4–6 weeks at a given dose
- Do not stop treatment abruptly without speaking to your prescriber first
Cost & Access
6. NHS Availability and 2026 UK Pricing
NHS availability and private prescription cost are major practical factors for UK patients considering these treatments. The landscape has changed significantly in 2025–2026 as NICE has assessed more treatments and supply has stabilised.
For patients paying privately, cost will typically be a significant consideration — particularly for treatments not yet on the NHS. The Wegovy injection at the standard 2.4mg dose currently offers the best combination of cost, NHS accessibility, and a long real-world track record for patients seeking an injectable option. The Wegovy Pill's pricing has not yet been confirmed by Novo Nordisk at the time of publication; Happy Pharmacy will update pricing information as soon as it is available.
For NHS-eligible patients — typically those accessing treatment through specialist weight management services — both the Wegovy 2.4mg injection and Mounjaro are currently available under NICE guidance. The higher-dose Wegovy 7.2mg injection and the Wegovy Pill are not yet available on the NHS and require a private prescription.
| Treatment | NHS Availability (2026) | Approx. Private Monthly Cost | MHRA Approved |
|---|---|---|---|
| Wegovy Pill (25mg daily) | Not yet — pending NICE assessment | Pricing TBC by Novo Nordisk; expected competitive with injection | June 2026 |
| Wegovy Injection (2.4mg weekly) | Yes — via specialist weight management services (TA875) | Approx. £130–£200/month (dose-dependent) | 2021 |
| Wegovy Injection (7.2mg weekly) | Not yet — pending NICE assessment | Approx. £329–£379/month | January 2026 |
| Mounjaro (5mg–15mg weekly) | Yes — via specialist weight management services (TA1026) | Approx. £149–£375/month (dose-dependent) | 2023 |
⚠️ Always Use a GPhC-Registered Pharmacy for Private Prescriptions
The popularity of weight loss treatments has led to a significant rise in unregulated online sellers offering medicines without proper clinical assessment. The MHRA has issued multiple warnings about counterfeit and substandard semaglutide and tirzepatide products circulating in the UK. Always obtain private prescriptions through a GPhC-registered pharmacy such as Happy Pharmacy (No. 9012585), where every patient undergoes a thorough clinical assessment.
Decision Guide
7. Which Treatment Is Right for You?
The best treatment is the one that fits your clinical profile, your lifestyle, and your goals. The decision should always be made in consultation with a qualified prescriber. The three-panel guide below summarises the key considerations.
Choose the Wegovy Pill If…
- You want to avoid all injections
- You can commit to a consistent daily morning routine
- Your BMI is 27–35 and you are new to GLP-1 treatment
- You have needle anxiety
- Comparable results to the 2.4mg injection are sufficient for your goals
- You prefer a daily tablet over a weekly injection
Choose the Wegovy Injection If…
- You want maximum flexibility — any time, with or without food
- You want access to the 7.2mg higher-dose option (~20.7% weight loss)
- You have already used Wegovy injection and found it manageable
- Your daily schedule is irregular or unpredictable
- You are eligible for NHS Wegovy prescribing
- You want the longest real-world track record of any GLP-1 treatment
Choose Mounjaro If…
- You want the highest average weight loss currently available (~22.5%)
- You have not responded adequately to GLP-1 monotherapy
- You want the dual GLP-1 + GIP mechanism for broader metabolic benefit
- You are comfortable with weekly injections
- Maximum efficacy is your primary clinical priority
ℹ️ A Note on Switching Treatments
It is possible to switch between the Wegovy Pill, Wegovy injection, and Mounjaro under clinical supervision. Some patients start on one treatment and move to another based on their response, tolerability, or changing priorities. Happy Pharmacy has dedicated guides on switching between treatments. Always consult your prescriber before making any changes.
Common Questions
Frequently Asked Questions
It depends on your priorities. Mounjaro produces greater average weight loss (~22.5% vs ~14–17%) and works via a dual GLP-1 and GIP mechanism — making it the stronger treatment on efficacy alone. The Wegovy Pill is the right choice if you want to avoid injections entirely, prefer a daily tablet routine, or are new to GLP-1 treatment and want to start with a well-evidenced needle-free option. A prescriber can assess which treatment is most appropriate for your BMI, health history, and goals.
Yes, on average clinical trial results, Mounjaro 15mg produces greater weight loss (~22.5%) than the Wegovy Pill (~14–17%). Mounjaro also activates a second hormonal pathway (GIP) that the Wegovy Pill does not, which is believed to explain its superior efficacy. However, individual responses vary — and the Wegovy Pill still delivers clinically significant, meaningful weight loss for the majority of patients who take it.
Yes — switching between GLP-1 and dual GLP-1/GIP treatments is possible under clinical supervision. If you did not respond adequately to Mounjaro, your prescriber may recommend a trial of semaglutide (Wegovy Pill or injection), or vice versa. Individual metabolic responses to different agents vary, and what works best for one patient may not be optimal for another.
Mounjaro private prescription costs range from approximately £149 to £375 per month depending on dose. The Wegovy Pill's UK price has not yet been confirmed by Novo Nordisk at the time of publication. The Wegovy 2.4mg injection is currently available on the NHS for eligible patients through specialist weight management services, making it effectively free at the point of use for those who qualify.
Not yet. The MHRA approved the Wegovy Pill in June 2026, but NHS availability requires a separate NICE cost-effectiveness assessment. Until then, it is available via private prescription from GPhC-registered pharmacies. The Wegovy 2.4mg injection and Mounjaro are both currently available on the NHS through specialist weight management services for eligible patients.
Yes, switching from Mounjaro to the Wegovy Pill is clinically possible and some patients choose to do so — for example, if they want to move to a needle-free treatment after reaching their weight loss goal on Mounjaro. Any switch requires a clinical review and should be managed by your prescriber to ensure safe transition between treatments.
Not Sure Which Treatment Is Right for You?
Happy Pharmacy is a GPhC-registered online pharmacy (No. 9012585). Our clinical team can assess your eligibility for the Wegovy Pill, Wegovy injection, or Mounjaro and help you choose the treatment that fits your goals and lifestyle. Trustpilot Rating: 4.8 ★
Book Your Free Consultation →
1. Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705–719. | 2. Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216. | 3. Efficacy and Safety of Semaglutide 7.2mg in Obesity — STEP UP Trial. American Diabetes Association, 2025. | 4. NICE. Tirzepatide for managing overweight and obesity (TA1026). NICE Technology Appraisal. January 2025. | 5. MHRA. Wegovy (semaglutide) oral tablet — approval summary. GOV.UK, June 2026. | 6. Electronic Medicines Compendium. Wegovy 1.5mg–25mg film-coated tablets — Summary of Product Characteristics. Novo Nordisk, 2026. | Happy Pharmacy (GPhC No. 9012585). The information in this guide is intended for general educational purposes only and does not replace personalised medical advice. Pricing information is accurate to the best of our knowledge at the time of publication and subject to change. Always consult a qualified healthcare professional before starting, stopping, or switching any prescription medicine.